ONE Lentiviral Vector Production System

ONE lentiviral vector production system from research to commercialization

Cost-effective lentiviral (LV) vector production is critical to meet commercial demand, and a smooth ramp-up to clinical production is essential. To address these needs, we have created a complete LV vector production system to help reduce costs and streamline your transition from research to clinical scale. The Gibco™ LV-MAX™ Lentiviral Production System is the first complete suspension production system. It can produce up to ten times more lentivirus, cutting costs by more than half compared to using polyethyleneimine (PEI)–based lentiviral production methods.

The first optimized GMP LV vector production system for suspension culture

The LV-MAX Lentiviral Production System:

• Cost-effective—Reduce cost by more than 50%*
• High titers—greater than 1 x 108 TU/mL (unconcentrated)
• Research-grade and GMP options—seamlessly transition from discovery to commercial production